Literature DB >> 10679743

Response of chemosensitive and chemoresistant leukemic cell lines to drug therapy: simultaneous assessment of proliferation, apoptosis, and necrosis.

J Boutonnat1, M Barbier, K Muirhead, M Mousseau, D Grunwald, X Ronot, D Seigneurin.   

Abstract

BACKGROUND: The balance between cell proliferation and drug-induced cell death by apoptosis or necrosis plays a major role in determining response to chemotherapy. Commonly-used DNA analysis methods cannot study both parameters simultaneously. A new approach described here combines a green fluorescent membrane-intercalating dye (PKH67) with Hoechst 33342 or annexin V and propidium iodide, to allow simultaneous assessment of cell division, cell cycle status, apoptosis, and necrosis, respectively.
METHODS: To test this approach, we used cultured K562 leukemic cell lines which are drug-sensitive (K562S) or drug-resistant (K562R) by virtue of whether they lack or exhibit expression, respectively, of the gp-170 (PGP) glycoprotein pump involved in multidrug resistance.
RESULTS: We found that: 1) PKH67 fluorescence intensity decreases proportionately to number of cell divisions, 2) labeling with PKH67 does not alter either cell cycle distribution, as assessed by vital DNA staining with Hoechst 33342, or cell growth, and 3) using a simple threshold analysis method suitable for real-time sorting decisions, subpopulations of proliferating cells present at initial levels of >/= 10% can readily be detected after two cell division times, based on decreased PKH67 intensity. Finally, we demonstrated that after treatment of an admixture of K562S and K562R with vincristine, triple-labeling with PKH67, annexin V, and propidium iodide can be used to identify and sort those cells which remain not only viable (nonnecrotic, nonapoptotic) but actively dividing (decreased PKH67 intensity) in the presence of drug.
CONCLUSIONS: Although the studies described here were carried out in a model system using cells having known drug resistance phenotypes, we expect that the methods described will be useful in ex vivo studies of clinical leukemic specimens designed to identify the role played by specific chemoresistance proteins and mechanisms in therapeutic outcomes for individual patients. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10679743

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  6 in total

1.  Innocuousness and intracellular distribution of PKH67: a fluorescent probe for cell proliferation assessment.

Authors:  C Rousselle; M Barbier; V V Comte; C Alcouffe; J Clement-Lacroix; G Chancel; X Ronot
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001 Nov-Dec       Impact factor: 2.416

2.  PKH26 can transfer to host cells in vitro and vivo.

Authors:  Peng Li; Run Zhang; Haitao Sun; Lei Chen; Fang Liu; Chen Yao; Mouxuan Du; Xiaodan Jiang
Journal:  Stem Cells Dev       Date:  2012-10-19       Impact factor: 3.272

3.  Identification and gene expression profiling of tumor-initiating cells isolated from human osteosarcoma cell lines in an orthotopic mouse model.

Authors:  Nino Rainusso; Tsz-Kwong Man; Ching C Lau; John Hicks; Jianhe J Shen; Alexander Yu; Lisa L Wang; Jeffrey M Rosen
Journal:  Cancer Biol Ther       Date:  2011-08-15       Impact factor: 4.742

4.  The response of newly established cell lines of Spodoptera littoralis to group I and group II baculoviruses.

Authors:  Ibrahim Ahmed; Holger Huebner; Yaseen Ismael Mamoori; Rainer Buchholz
Journal:  Cytotechnology       Date:  2019-05-08       Impact factor: 2.058

5.  Usefulness of PKH fluorescent labelling to study leukemic cell proliferation with various cytostatic drugs or acetyl tetrapeptide--AcSDKP.

Authors:  Jean Boutonnat; Anne-Marie Faussat; Jean-Pierre Marie; Jérôme Bignon; Johanna Wdzieczak-Bakala; Magali Barbier; Josiane Thierry; Xavier Ronot; Pierre-Emmanuel Colle
Journal:  BMC Cancer       Date:  2005-09-20       Impact factor: 4.430

6.  Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma.

Authors:  Hiroyuki Kashiwagi; Jonathan E McDunn; Peter O Simon; Peter S Goedegebuure; Suwanna Vangveravong; Katherine Chang; Richard S Hotchkiss; Robert H Mach; William G Hawkins
Journal:  J Transl Med       Date:  2009-03-26       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.